PCYC Key Stats
- Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Winner May 23
- PHARMACYCLICS INC Files SEC form 8-K, Amendment or Waiver to Code of Ethics May 23
- 5 Stocks Raising The Drugs Industry Higher May 23
- FDA Designation for Synageva Candidate - Analyst Blog Zacks May 22
- FDA Designation for Synageva Candidate May 22
- PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statem... May 21
- 2013 FDA Drug Approval Calendar May 21
- Tackling Cancer: Leukemia's Biggest Current and Upcoming Players May 19
- Wall Street Transcript Interview with Finny Kuruvilla, Portfolio Manager of the ... May 16
- PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statem... May 15
PCYC Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Pharmacyclics is up 159.4% over the last year vs S&P 500 Total Return up 27.77%, Johnson & Johnson up 42.25%, and Catalyst Pharmaceutical Partners up 54.37%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Pro Ratings for PCYC
Pro Report PDF for PCYC
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download PCYC Pro Report PDF
Pro Strategies Featuring PCYC
Did Pharmacyclics make it into our Pro Portfolio Strategies?
Pharmacyclics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Its clinical development and product candidates are small-molecule enzyme inhibitors designed to target key biochemical pathways involved in human diseases with critical unmet needs. The company has three proprietary drug candidates under clinical development and several preclinical lead molecules which includes Bruton's tyrosine kinase inhibitor, Btk inhibitor lead optimization program and histone deacetylase inhibitor. The company was founded on April 19, 1991 and is headquartered in Sunnyvale, California.